<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00827567</url>
  </required_header>
  <id_info>
    <org_study_id>RAD001JUS48T</org_study_id>
    <nct_id>NCT00827567</nct_id>
  </id_info>
  <brief_title>Trial of RAD001 in Triple Negative Metastatic Breast Cancer</brief_title>
  <official_title>A Phase II Trial of RAD001 in Triple Negative Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis of this clinical research study is to discover if the study drug RAD001 can
      shrink or slow the growth of Estrogen Receptor/Progesterone Receptor (ER/PR) negative or
      Human Epidermal growth factor Receptor 2 (Her2 Neu) negative breast cancer. The safety of
      RAD001 will also be studied. Patients physical state, symptoms, changes in the size of the
      tumor, and laboratory findings obtained while on-study will help the research team decide if
      RAD001 is safe and effective.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RAD001 is an orally administered cell cycle inhibitor with antitumor activity. RAD001, like
      Rapamycin, binds with high affinity to an intracellular immunophilin, FKBP12 and this complex
      specifically interacts with the mammalian target of rapamycin (mTOR) protein kinase,
      inhibiting downstream events such as the initiation of mRNA translation. RAD001 inhibits the
      growth of a wide range of histologically diverse tumor cells. RAD001 is being developed as a
      cytostatic agent to delay the time to tumor recurrence/progression or to increase survival in
      patients with various malignancies. The compound has good tolerability, a partially
      discovered mechanism of action. RAD001 has the ability to arrest cells in the G1 phase, and
      the ability to induce apoptosis. RAD001 is being investigated as an anticancer agent based on
      its potential to act directly on the tumor cells by inhibiting tumor cell growth and
      proliferation through possible inhibition of the PI3/AKT/MTOR pathway.

      RAD001 was shown to have activity in human tumor cell lines originating from lung, breast,
      prostate, colon, kidney, melanoma and glioblastoma. RAD001 was also shown to have activity in
      human pancreatic neuroendocrine cells, where induction of apoptosis was reported, as well as
      in acute myeloid leukemia cells, adult T-cell leukemia cells, diffuse large B cell lymphoma
      cells, pancreatic tumor cells, ovarian cancer cells, and hepatocellular carcinoma cells.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow accrual
  </why_stopped>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Progression(TTP)</measure>
    <time_frame>Each patient assessed at 8 weeks from start of study drug</time_frame>
    <description>Progression is defined by RESIST criteria as any new lesion or the sum of target lesions increasing by 20% over baseline</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>RAD 001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RAD001-10 mg by mouth once everyday</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RAD 001</intervention_name>
    <description>RAD 001-10 mg by mouth once everyday</description>
    <arm_group_label>RAD 001</arm_group_label>
    <other_name>Everolimus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eastern Cooperative Group (ECOG) performance status ≤ 2

          -  Age ≥ 18 years

          -  At least one measurable site of disease according to RECIST criteria that has not been
             previously irradiated. If the patient has had previous radiation to the marker
             lesion(s), there must be evidence of disease progression since the radiation

          -  Adequate bone marrow function as shown by: Absolute Neutrophil Count (ANC) ≥ 1.5 x
             109/L, Platelets (PLT)≥ 100 x 109/L, Hemoglobin (HGB) ≥9 g/dL

          -  Adequate liver function as shown by:Serum bilirubin ≤ 1.5 x upper limits of normal
             (ULN), Prothrombin Time (INR) ≤ 1.3 (or ≤ 3 on anticoagulants), Liver function teats ≤
             2.5x ULN (≤ 5x ULN in patients with liver metastases)

          -  Adequate renal function: serum creatinine ≤ 1.5 x ULN

          -  Controlled diabetes as defined by fasting serum glucose ≤1.5 x ULN

          -  Fasting serum cholesterol ≤300 mg/dL or ≤7.75 mmol/L AND fasting triglycerides ≤ 2.5 x
             ULN.

        Exclusion Criteria:

          -  Currently receiving anticancer therapies or who have received anticancer therapies
             within 4 weeks of the start of study drug (including chemotherapy, antibody based
             therapy, etc.)

          -  Palliative radiation therapy only allowed to localized areas (ie: painful rib lesion),
             at the discretion of the PI and treating radiation oncologist

          -  Major surgery/significant traumatic injury within 4 weeks of start of study drug.

          -  Not recovered from the side effects of any major surgery (defined as requiring general
             anesthesia) to Grade I or patients that may require major surgery during the course of
             the study.

          -  Prior treatment with any investigational drug within the preceding 4 weeks

          -  Receiving chronic immunosuppressive agents, except corticosteroids with a daily dosage
             equivalent to prednisone ≤ 20 milligrams (mg). However, patients receiving
             corticosteroids must have been on a stable dosage regimen for a minimum of 4 weeks
             prior to the first treatment with RAD001. Topical or inhaled corticosteroids are
             allowed.

          -  May not receive immunization with attenuated live vaccines within one week of study
             entry or during study period.

          -  Uncontrolled brain or leptomeningeal metastases, including patients who continue to
             require glucocorticoids for brain or leptomeningeal metastases

          -  Other malignancies within the past 3 years, except for adequately treated carcinoma of
             the cervix and basal or squamous cell carcinomas of the skin.

          -  Severe and/or uncontrolled medical conditions or other conditions that could affect
             their participation in the study such as: Congestive heart failure: New York Heart
             Association Class III/IV, Unstable angina pectoris, symptomatic congestive heart
             failure, myocardial infarction within 6 months of start of study drug, serious
             uncontrolled cardiac arrhythmia or any other clinically significant cardiac disease.

          -  Impaired lung function (PFT screen at baseline) as defined as spirometry and DLCO that
             is 50% of the normal predicted value and/or 02 saturation that is 88% or less at rest
             on room air.

          -  Uncontrolled diabetes as defined by fasting serum glucose ≥1.5 x ULN. Glucose control
             should be achieved before starting a patient on RAD001.

          -  Active (acute or chronic) or uncontrolled severe infections

          -  Liver disease(cirrhosis, chronic active hepatitis or chronic persistent hepatitis)

          -  Known history of Human Immunodeficiency Virus (HIV) seropositivity

          -  Impairment of gastrointestinal function/disease that may significantly alter the
             absorption of RAD001 (e.g., ulcerative disease, uncontrolled nausea, vomiting,
             diarrhea, malabsorption syndrome or small bowel resection)

          -  Active, bleeding diathesis

          -  Female patients who are pregnant or breast feeding, or adults of reproductive
             potential who are not using effective birth control methods.

          -  Prior treatment with an mTOR inhibitor (sirolimus, temsirolimus, everolimus).

          -  Known hypersensitivity to RAD001 (everolimus) or other rapamycin drugs (sirolimus,
             temsirolimus) or to its excipients
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Allan Lipton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn State Milton S. Hershey</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Penn State Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou SH, Marshall B, Boni JP, Dukart G, Sherman ML. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004 Mar 1;22(5):909-18.</citation>
    <PMID>14990647</PMID>
  </reference>
  <reference>
    <citation>Baselga, J. et al. Improved clinical and cell cycle response with an mTOR inhibitor, daily oral RAD001 (everolimus) plus letrozole versus placebo plus letrozole in a randomized phase II neoadjuvant trial in ER+ breast cancer. J Clin Oncol 26: 2008 (May 20 suppl; abstr 530)</citation>
  </reference>
  <reference>
    <citation>Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer. 2004 May;4(5):335-48. Review.</citation>
    <PMID>15122205</PMID>
  </reference>
  <reference>
    <citation>Bose S, Chandran S, Mirocha JM, Bose N. The Akt pathway in human breast cancer: a tissue-array-based analysis. Mod Pathol. 2006 Feb;19(2):238-45.</citation>
    <PMID>16341149</PMID>
  </reference>
  <reference>
    <citation>Boulay A, Lane HA. The mammalian target of rapamycin kinase and tumor growth inhibition. Recent Results Cancer Res. 2007;172:99-124. Review.</citation>
    <PMID>17607938</PMID>
  </reference>
  <reference>
    <citation>Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Valantine-von Kaeppler HA, Starling RC, Sørensen K, Hummel M, Lind JM, Abeywickrama KH, Bernhardt P; RAD B253 Study Group. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med. 2003 Aug 28;349(9):847-58.</citation>
    <PMID>12944570</PMID>
  </reference>
  <reference>
    <citation>Haritunians T, Mori A, O'Kelly J, Luong QT, Giles FJ, Koeffler HP. Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia. 2007 Feb;21(2):333-9. Epub 2006 Nov 30.</citation>
    <PMID>17136116</PMID>
  </reference>
  <reference>
    <citation>Ingelman-Sundberg M. Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Naunyn Schmiedebergs Arch Pharmacol. 2004 Jan;369(1):89-104. Epub 2003 Oct 22. Review.</citation>
    <PMID>14574440</PMID>
  </reference>
  <reference>
    <citation>Ikezoe T, Nishioka C, Bandobashi K, Yang Y, Kuwayama Y, Adachi Y, Takeuchi T, Koeffler HP, Taguchi H. Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells. Leuk Res. 2007 May;31(5):673-82. Epub 2006 Sep 27.</citation>
    <PMID>17007924</PMID>
  </reference>
  <reference>
    <citation>Jerusalem G.H et al. Multicenter phase I clinical trial of daily and weekly RAD001 in combination with vinorelbine and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab. J Clin Oncol 26: 2008 (May 20 suppl; abstr 1057)</citation>
  </reference>
  <reference>
    <citation>Tanaka C, O'Reilly T, Kovarik JM, Shand N, Hazell K, Judson I, Raymond E, Zumstein-Mecker S, Stephan C, Boulay A, Hattenberger M, Thomas G, Lane HA. Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol. 2008 Apr 1;26(10):1596-602. doi: 10.1200/JCO.2007.14.1127. Epub 2008 Mar 10.</citation>
    <PMID>18332467</PMID>
  </reference>
  <reference>
    <citation>Mabuchi S, Altomare DA, Cheung M, Zhang L, Poulikakos PI, Hensley HH, Schilder RJ, Ozols RF, Testa JR. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res. 2007 Jul 15;13(14):4261-70.</citation>
    <PMID>17634556</PMID>
  </reference>
  <reference>
    <citation>Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 2007 Jun 29;129(7):1261-74. Review.</citation>
    <PMID>17604717</PMID>
  </reference>
  <reference>
    <citation>Mondesire WH, Jian W, Zhang H, Ensor J, Hung MC, Mills GB, Meric-Bernstam F. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res. 2004 Oct 15;10(20):7031-42.</citation>
    <PMID>15501983</PMID>
  </reference>
  <reference>
    <citation>Sieghart W, Fuereder T, Schmid K, Cejka D, Werzowa J, Wrba F, Wang X, Gruber D, Rasoul-Rockenschaub S, Peck-Radosavljevic M, Wacheck V. Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation. Transplantation. 2007 Feb 27;83(4):425-32.</citation>
    <PMID>17318075</PMID>
  </reference>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2009</study_first_submitted>
  <study_first_submitted_qc>January 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2009</study_first_posted>
  <results_first_submitted>August 16, 2011</results_first_submitted>
  <results_first_submitted_qc>March 15, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 20, 2012</results_first_posted>
  <last_update_submitted>December 11, 2013</last_update_submitted>
  <last_update_submitted_qc>December 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>Allan Lipton</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>metastatic breast</keyword>
  <keyword>triple negative</keyword>
  <keyword>ER/PR negative</keyword>
  <keyword>Her2 Neu negative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period 4/13/2009 through 2/25/2011. Protocol dated 3/6/2009 &amp; consent dated 4/8/2009 for the 4/13/2009 approval.Patients were seen at Penn State Cancer Institute Outpatient Unit.</recruitment_details>
      <pre_assignment_details>Two of the patients that were screen failures had cholesterol levels higher than inclusion criteria as this drug may increase cholesterol levels they were not eligible.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>RAD 001</title>
          <description>RAD001-10 mg by mouth once everyday</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">2 screen failures, 4 withdrew from study to go on to other therapies</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Progression of Disease/Screen Failure</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>RAD 001</title>
          <description>RAD001-10 mg by mouth once everyday</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.5" spread="7.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Progression(TTP)</title>
        <description>Progression is defined by RESIST criteria as any new lesion or the sum of target lesions increasing by 20% over baseline</description>
        <time_frame>Each patient assessed at 8 weeks from start of study drug</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RAD 001</title>
            <description>RAD001-10 mg by mouth once everyday</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression(TTP)</title>
          <description>Progression is defined by RESIST criteria as any new lesion or the sum of target lesions increasing by 20% over baseline</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Weekly for 4 weeks, then monthly until disease progression</time_frame>
      <group_list>
        <group group_id="E1">
          <title>RAD 001</title>
          <description>RAD001-10 mg by mouth once everyday</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Allan Lipton, MD</name_or_title>
      <organization>Penn State</organization>
      <phone>717-531-5960</phone>
      <email>alipton@psu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

